Holen Sie sich die Stockscreener-App
0.9341
0.11%
-0.001
Vorhandelsmarkt:
.92
-0.0141
-1.51%
Schlusskurs vom Vortag:
$0.9351
Offen:
$0.93
24-Stunden-Volumen:
622.94K
Relative Volume:
1.04
Marktkapitalisierung:
$43.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.7984
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
+0.04%
1M Leistung:
-8.42%
6M Leistung:
-32.31%
1J Leistung:
-70.81%
1-Tages-Spanne:
$0.9101
$0.9586
1-Wochen-Bereich:
$0.90
$1.16
52-Wochen-Spanne:
$0.8505
$3.405
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.9341 | 43.97M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
Tools to assess PDS Biotechnology Corporation’s risk profile2025 Dividend Review & Fast Gaining Stock Strategy Reports - newser.com
Will PDS Biotechnology Corporation stock go up soonEarnings Overview Summary & Free High Accuracy Swing Entry Alerts - newser.com
Is PDS Biotechnology Corporation stock positioned for long term growthJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Why PDS Biotechnology Corporation stock is recommended by analystsJuly 2025 Movers & Precise Swing Trade Entry Alerts - newser.com
Is PDS Biotechnology Corporation stock entering bullish territoryTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsJuly 2025 PreEarnings & Consistent Profit Trading Strategies - newser.com
Earnings visualization tools for PDS Biotechnology CorporationTrend Reversal & Reliable Trade Execution Plans - newser.com
What machine learning models say about PDS Biotechnology CorporationCPI Data & Fast Moving Trade Plans - newser.com
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval - Stocktwits
Building trade automation scripts for PDS Biotechnology CorporationTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
PDS Biotechnology Seeks Accelerated FDA Pathway for Cancer Therapy - AD HOC NEWS
What dividend safety score for PDS Biotechnology Corporation stockTrade Volume Summary & Fast Moving Market Watchlists - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces New Clinical and Translational Data on Pds0101 and Pds01adc to Be Presented At the 2025 Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
PDS Biotech stock soars after seeking expedited approval pathway for cancer drug - Investing.com India
PDS Biotech to seek expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer - MarketScreener
PDS Biotechnology Corporation Seeks Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Following Promising VERSATILE-002 Trial Results - Quiver Quantitative
PDSB seeks FDA meeting to explore expedited path for PDS0101 - Stock Titan
39.3-month mOS seen with PDS0101 as PDS Biotech (NASDAQ: PDSB) seeks FDA expedited path - Stock Titan
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):